Aura Biosciences reported strong progress in its Phase 3 CoMpass trial for early choroidal melanoma, aiming to complete enrollment by mid-2026 with topline data expected in the second half of 2027. The company is also advancing a Phase 1b/2 trial for bladder cancer, with initial data due mid-2026, and has achieved 12-month stability for a new drug formulation targeting non-ocular solid tumors. With $144.2 million in cash, Aura is well-funded to continue its clinical programs focused on vision-preserving cancer therapies, potentially transforming treatment for several solid tumors.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
